Gemcitabine plus cisplatin versus chemoradiotherapy in locally advance

I can’t reference where I read it, but I know I did read somewhere at the start of my researching information, that in very rare diseases, studies sometimes ended before they were planned to end, due to not having enough participants for the study…the problem of a rare disease. There aren’t enough people with the disease at any one point in the disease process required for a particular study. However, IMO, I would think that if any of those studies showed any great promise, there would be even the few patients available clamoring to get into the study.

Closing a trial early due to low participation – is this common?

Duke